It’s crucial when treating osteoarthritis to break that cycle and treat the disease. I find that joint supplements are a very effective and risk-free way of doing that and it’s good to have data that supports what I see in my clinical practice everyday.
Boston, MA (PRWEB) December 8, 2005
A poster presentation taking place on Friday looks at the differential effects of chondroitin sulfate on osteoarthritis symptoms related to degree of radiographic involvement. When treating osteoarthritis, doctors look to treat two specific targets—pain and the progression of the disease. While the overall results of the NIH GAIT study have focused purely on pain measured on the WOMAC scale, many other results with different measurement scales are emerging. This latest data is significant because it is using the Kellgren and Lawrence scale, which is another way to evaluate the joint and the phase of the disease in an osteoarthritis patient, by looking into the radiographic evaluation of a joint.
The patients that were evaluated were in two specific groups on the K&L scale: Groups 2 and 3, where the measurement of space between the joints was minimal (2), or moderate (3). Basically the results showed that patients in Group 2 showed significant improvement with chondroitin sulfate vs. placebo in stiffness, function and joint swelling and in Group 3, joint swelling was reduced.
Doctors treating patients are always concerned about how to stop or reverse the progression of osteoarthritis. Getting the pain under control is the first step, but then dealing with all the other symptoms such as joint swelling, stiffness and function are as important. It’s a vicious cycle, joint swelling in 90% of patients is caused by joint effusion. Joint effusion is an increase of liquid inside the articular space—it produces pain and functional incapacity. Says Nicholas DiNubile, MD an orthapeodic surgeon “ It’s crucial when treating osteoarthritis to break that cycle and treat the disease. I find that joint supplements are a very effective and risk-free way of doing that and it’s good to have data that supports what I see in my clinical practice everyday.” Dr. DiNubile has over 25 years experience in treating osteoarthritis. Chosen as one of the “Best Doctors in America”, DiNubile has been the recipient of the prestigious Healthy American Fitness Leaders award and also served as special advisor and medical consultant to The President’s Council on Physical Fitness and Sports under the first Bush Administration.
The information contained in this release was extracted from the poster being presented at the conference by Dr.Clegg, lead researcher on the GAIT study. Dr. Clegg concluded that the results suggest chondroitin sulfate may improve osteoarthritis knee pain in patients with relatively early radiographic disease.
Bioiberica is the leading manufacturer of pharmaceutical-grade chondroitin sulfate and was selected by the NIH as the exclusive supplier of chondroitin sulfate for the GAIT study.
For more information, or to arrange an interview with a company spokesperson or a member of the medical advisory panel, please contact Leesa Raab at ADinfinitum, 212-693-2150 Ext. 309.
# # #